Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $3.34, for a total transaction of $100,200.00. Following the completion of the sale, the director owned 6,158,287 shares of the company’s stock, valued at approximately $20,568,678.58. The trade was a 0.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, August 4th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.25, for a total transaction of $97,500.00.
• On Tuesday, July 7th, Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00.

Recursion Pharmaceuticals Trading Up 1.8%

NASDAQ RXRX opened at $3.44 on Friday. Recursion Pharmaceuticals, Inc. has a 1-year low of $2.77 and a 1-year high of $7.18. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.84 billion, a PE ratio of -3.31 and a beta of 1.07. The firm’s fifty day simple moving average is $3.33 and its 200-day simple moving average is $3.33.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The firm had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $10.97 million. During the same quarter in the prior year, the business posted ($0.41) earnings per share. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, August 17th. Finally, Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.06.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC boosted its stake in shares of Recursion Pharmaceuticals by 28.1% during the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock worth $56,000 after acquiring an additional 2,428 shares in the last quarter. Equitable Holdings Inc. raised its stake in shares of Recursion Pharmaceuticals by 7.1% in the 3rd quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock valued at $192,000 after acquiring an additional 2,600 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in shares of Recursion Pharmaceuticals by 29.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,706 shares of the company’s stock valued at $64,000 after acquiring an additional 2,883 shares in the last quarter. Ascent Wealth Partners LLC lifted its holdings in Recursion Pharmaceuticals by 11.8% in the 1st quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company’s stock worth $86,000 after purchasing an additional 2,974 shares during the last quarter. Finally, Benjamin Edwards Inc. lifted its holdings in Recursion Pharmaceuticals by 2.5% in the 4th quarter. Benjamin Edwards Inc. now owns 146,789 shares of the company’s stock worth $600,000 after purchasing an additional 3,625 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.